Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 3/20 | 0.35 |
| ▸ | AGER | Q15109 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7670360 | 0.86 | ESR1 (0.38) | TAAR1HTR2AIDO1ALDH1A1 | |
| SCHEMBL18492177 | 0.80 | TAAR1 (0.40) | TAAR1HTR2ACYP2A6IDO1ALDH1A1 | |
| SCHEMBL16685648 | 0.80 | ESR1 (0.43) | TAAR1HTR2ACYP2A6IDO1ALDH1A1 | |
| SCHEMBL25471464 | 0.79 | TRPA1 (0.43) | ALDH1A1 | |
| SCHEMBL23616397 | 0.78 | CA1 (0.41) | TAAR1HTR2ACYP2A6IDO1ALDH1A1 | |
| SCHEMBL16572213 | 0.78 | TAAR1 (0.38) | TAAR1HTR2ACYP2A6IDO1ALDH1A1 | |
| SCHEMBL11648 | 0.77 | TAAR1 (0.37) | TAAR1HTR2ACYP2A6IDO1ALDH1A1 | |
| SCHEMBL10248786 | 0.76 | IDO1 (0.48) | TAAR1IDO1 | |
| SCHEMBL10570 | 0.76 | ALDH1A1 (0.52) | TAAR1ALDH1A1 | |
| SCHEMBL11103061 | 0.75 | TAAR1 (0.50) | TAAR1HTR2ACYP2A6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| EP-4423075-B1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| WO-2025077856-A1 | TRICYCLIC-CARBONYL-NITROGEN HETEROCYCLIC DERIVATIVES AND USE THEREOF | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2025-04-17 | — | — | WO | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-09 | — | — | US | disclosed |
| EP-4423075-A1 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024109919-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-1987092-A1 | FLUORINATED RYLENETETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1966206-A1 | NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080090325-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080017850-A1 | applying n-type organic semiconducting compound 1,6,7,12-Tetrachloro-N,N'-benzyl-perylene-3,9; 11,12-tetracarboxylic diimide or 1,6,7,12-tetrachloroperylen-3,9; 9,10-tetracarboxylic dianhydride; charge transfer compounds for electronics, optoelectronics and photonic applications; chemical intermediates | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007128774-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | BASF SE (DE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259475-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007093643-A1 | FLUORINATED RYLENETETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007074137-A1 | NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2007-07-05 | — | — | WO | disclosed |
| CN-1638757-A | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA INC (CA) | 2005-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR4 | TAAR1 169/4885HTR2A 1438/4885CYP2A6 202/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | TAAR1 2545/4885HTR2A 2088/4885CYP2A6 266/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | TAAR1 1078/4885HTR2A 1774/4885CYP2A6 3551/4885 |
| US-20080090325-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | POF1B, RCOR1, RCOR3 | TAAR1 378/4885HTR2A 2535/4885CYP2A6 1816/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | TAAR1 57/4885HTR2A 270/4885CYP2A6 40/4885 |
| US-20080017850-A1 | applying n-type organic semiconducting compound 1,6,7,12-Tetrachloro-N,N'-benzyl-perylene-3,9; 11,12-tetracarboxylic diimide or 1,6,7,12-tetrachloroperylen-3,9; 9,10-tetracarboxylic dianhydride; charge transfer compounds for electronics, optoelectronics and photonic applications; chemical intermediates | POF1B, NR2C2, NR2E1 | TAAR1 669/4885HTR2A 2546/4885CYP2A6 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.